CN103228656B - 3-取代基-6-(吡啶基甲氧基)-吡咯并吡啶化合物 - Google Patents

3-取代基-6-(吡啶基甲氧基)-吡咯并吡啶化合物 Download PDF

Info

Publication number
CN103228656B
CN103228656B CN201180058194.5A CN201180058194A CN103228656B CN 103228656 B CN103228656 B CN 103228656B CN 201180058194 A CN201180058194 A CN 201180058194A CN 103228656 B CN103228656 B CN 103228656B
Authority
CN
China
Prior art keywords
methyl
compound
pyridine
pyrrolo
mmoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180058194.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103228656A (zh
Inventor
C.拉马斯－佩泰拉
S.J.理查兹
S.萨普马斯
M.W.瓦尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN103228656A publication Critical patent/CN103228656A/zh
Application granted granted Critical
Publication of CN103228656B publication Critical patent/CN103228656B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180058194.5A 2010-12-02 2011-11-17 3-取代基-6-(吡啶基甲氧基)-吡咯并吡啶化合物 Expired - Fee Related CN103228656B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10382325 2010-12-02
EP10382325.8 2010-12-02
US201161439438P 2011-02-04 2011-02-04
US61/439438 2011-02-04
PCT/US2011/061212 WO2012074769A1 (en) 2010-12-02 2011-11-17 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds

Publications (2)

Publication Number Publication Date
CN103228656A CN103228656A (zh) 2013-07-31
CN103228656B true CN103228656B (zh) 2015-09-30

Family

ID=45023893

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180058194.5A Expired - Fee Related CN103228656B (zh) 2010-12-02 2011-11-17 3-取代基-6-(吡啶基甲氧基)-吡咯并吡啶化合物

Country Status (12)

Country Link
US (1) US8778946B2 (ru)
EP (1) EP2646437B1 (ru)
JP (1) JP5837938B2 (ru)
KR (1) KR101547407B1 (ru)
CN (1) CN103228656B (ru)
AU (1) AU2011337041B2 (ru)
BR (1) BR112013012494A2 (ru)
CA (1) CA2819840C (ru)
EA (1) EA021781B1 (ru)
ES (1) ES2523282T3 (ru)
MX (1) MX2013006185A (ru)
WO (1) WO2012074769A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2509937A (en) 2013-01-17 2014-07-23 Nec Corp Providing security information to a mobile device in which user plane data and control plane signalling are communicated via different base stations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1118598A (zh) * 1993-03-01 1996-03-13 默克·夏普-道姆公司 吡咯并吡啶衍生物
WO2005056524A2 (en) * 2003-12-09 2005-06-23 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2010124047A1 (en) * 2009-04-23 2010-10-28 Wyeth Llc Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245540A1 (en) 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
JP2007523936A (ja) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー ヘテロアリール縮合ピラゾロ誘導体
WO2006006610A1 (ja) * 2004-07-09 2006-01-19 Banyu Pharmaceutical Co., Ltd オキソピペラジン誘導体
WO2007010965A1 (ja) * 2005-07-22 2007-01-25 Shionogi & Co., Ltd. Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
WO2007098418A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
WO2009143404A1 (en) * 2008-05-23 2009-11-26 Wyeth Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
US8012992B2 (en) 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1118598A (zh) * 1993-03-01 1996-03-13 默克·夏普-道姆公司 吡咯并吡啶衍生物
WO2005056524A2 (en) * 2003-12-09 2005-06-23 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2010124047A1 (en) * 2009-04-23 2010-10-28 Wyeth Llc Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5)

Also Published As

Publication number Publication date
KR101547407B1 (ko) 2015-08-25
AU2011337041A1 (en) 2013-05-23
MX2013006185A (es) 2013-07-15
JP2013544836A (ja) 2013-12-19
US20130225602A1 (en) 2013-08-29
EA201390619A1 (ru) 2013-11-29
US8778946B2 (en) 2014-07-15
KR20130087027A (ko) 2013-08-05
CN103228656A (zh) 2013-07-31
AU2011337041B2 (en) 2015-05-14
JP5837938B2 (ja) 2015-12-24
EP2646437B1 (en) 2014-09-03
CA2819840C (en) 2015-05-26
EP2646437A1 (en) 2013-10-09
CA2819840A1 (en) 2012-06-07
BR112013012494A2 (pt) 2016-09-06
ES2523282T3 (es) 2014-11-24
WO2012074769A1 (en) 2012-06-07
EA021781B1 (ru) 2015-08-31

Similar Documents

Publication Publication Date Title
US11254681B2 (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
CA2908098A1 (en) Mk2 inhibitors and uses thereof
CN108779096A (zh) 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
WO2005085252A1 (en) Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
JP2021506882A (ja) メニン−ｍｌｌ相互作用のエキソ−アザスピロ阻害剤
CN109134448A (zh) 杂环化合物及其盐、制备方法、用途和药物
CN110483521A (zh) 一种可逆共价布鲁顿酪氨酸激酶抑制剂、药物组合物及其应用
Elsner et al. Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists
TW202241902A (zh) 一種嘧啶并五元氮雜環類衍生物的晶型及其製備方法
Chen et al. Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo [d] isothiazol-3-yl) piperazin-1-yl) ethyl) cyclohexyl) amides as potential multireceptor atypical antipsychotics
Blokhina et al. Solid–liquid phase equilibrium and thermodynamic analysis of novel thiazolidine-2, 4-dione derivative in different solvents
CN103228656B (zh) 3-取代基-6-(吡啶基甲氧基)-吡咯并吡啶化合物
Modica et al. Design, synthesis and binding properties of novel and selective 5-HT3 and 5-HT4 receptor ligands
CN109641909A (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
CN104418866B (zh) Dgat1抑制剂及其制备方法和用途
JP2024520969A (ja) Ｗｅｅ１阻害剤とその用途
Modica et al. Design, synthesis and binding properties of novel and selective 5-HT3 and 5-HT4 receptor ligands
CN109890823A (zh) 稠合氮杂环化合物及其作为ampa受体调节剂的用途
CN107459491A (zh) 含1,2,3‑三氮唑结构的苯甲酰胺类化合物及其用途
TW200413339A (en) Aryl and heteroaryl morpholine derivatives
RU2795096C2 (ru) аЭКЗО-АЗАСПИРО-ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕНИН-MLL
CN112500353B (zh) 一种左西孟旦的前药化合物、制备方法及其应用
AU2021314419B2 (en) Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof
WO2024109676A1 (zh) 具有btk抑制作用的吡唑并嘧啶衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150930

Termination date: 20201117